Free Initial Consultation
Toll Free:
defective drug attorneys st louis

Widow files wrongful death lawsuit against Plavix manufacturer

Millions of Americans take prescription medications aimed to combat chronic conditions and diseases such as heart disease. For individuals who have recently suffered a heart attack or stroke, these medications are often deemed as medically necessary to prevent an individual from suffering another cardiac event or stroke. Unfortunately, these prescription drugs are not without side effects many of which are unpleasant and even potentially dangerous.

A woman recently filed a wrongful death lawsuit against the makers of the prescription drug Plavix. Marketed towards individuals who have already suffered a heart attack or stroke as a drug used to prevent blood clots, Plavix is taken by thousands of Americans.

The woman filed the wrongful death lawsuit over claims that the drug caused her late husband to suffer a brain hemorrhage and die. In the lawsuit, the woman asserts her 54-year-old husband began taking Plavix in 2009. Two years later, a blood vessel in the man’s brain burst and he died.

According to the lawsuit, the plaintiff claims the defendants are negligent in failing to warn individuals about the drug’s many risks and dangerous side effects. The defendants, who include the drug-maker Bristol-Myers Squibb Co., are accused of strict liability and manufacturing and marketing a defective drug.

The plaintiff is seeking damages related to the loss of her husband as well as medical expenses and lost wages. Individuals who have lost a loved one who was taking Plavix or a similar prescription drug may also choose to take legal action. While nothing can bring a loved one back, in many cases wrongful death cases result in plaintiffs being awarded monies that can be used to eliminate medical debt and offset lost earnings.

Source: The Southeast Texas Record, “Wrongful death lawsuit filed over Huntington man’s use of Plavix prescription drug,” Michelle Keahey, May 31, 2013


Privacy Policy | Business Development Solutions by FindLaw, a Thomson Reuters business.